Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Post by Stockhunton Sep 12, 2014 11:28am

188 Views

Post# 22930626

GVN Experts Answer Questions on Mankind’s Worst Ebola Outb

On Friday, September 12 between 1 pm EDT to 2 pm EDT the GVN, with support from UST Global as a technology partner, will host a WebEx conference including three GVN world-renowned Ebola experts and journalists from across the globe. All journalists can register here and will receive login information.

GVN’s Ebola experts will discuss current treatment strategies, unapproved treatments that have been used in the current outbreak or that will soon be available, and vaccine development. They will explain why this outbreak is more deadly than others and what governments could do to contain future outbreaks. Each will also discuss their personal experience and role in this Ebola outbreak.

Webconference

Bullboard Posts

Know your gold investment options, from bullion dealers to Costco